indian stock market

BUY COLGATE POLMOLIVECMPRS 386 TARGET RS 548(2YRS)EQM dhoot industrial finanace ltd cmp32.55 p/e 4.2 only mutibaggger(kr choksey) Alpha Geo (India) Buy Rs 713.75 Havell's India Buy Rs 646.90 Indian Overseas Bank Buy Rs 168.80 VARUN SHIPPING CMPrs84 target106 (12 months) buy ndtv cmpRS436 target RS484 buy cmc cmprs1188 targer1325 slrs 1143

Event § We believe that India will be in a ‘sweet spot’ in 2008, with domestic growth bolstered by capital flows even as the US slows without slipping into recession. We explore the key themes that we think will dominate 2008. Impact § The economy. In terms of macroeconomic factors, we see a “sweet spot” scenario playing out for India. Growth will slow slightly in the first half of the year, but much of that is already in expectations. We believe that the US will not slip into recession but could escape with a slowdown – which should keep liquidity abundant and, despite the RBI’s concerns, interest rates drifting down. All this plays out into a sharp bounceback in 2H08. The big risk is, however, that we are wrong on the US and there indeed is a recession; India will offer plenty of places to hide in that scenario. Our pick is telecoms. § Policy – elections cloud the scenario. Policy will be dominated by elections – scheduled in 1Q09 but possibly brought forward by a fluid political

Bharti Airtel CMP:Rs 914.60 Target Price: NA CLSA has initiated coverage on Bharti with a 'buy' rating on the back of expectations that the company would do well as India's mobile subscriber base is set to grow at 33% CAGR to 383 million by FY10, implying a penetration of 31%. "Bharti's subscriber growth is on track to meet our forecasts of 108 million by FY10 CL and despite an intensely competitive environment, it has raised market share (up 200 bps y-o-y) as well as expanded margins (368 bps y-o-y to 42.8% in Q208)." The success of Bharti's growing suite of value-added services will aid in mitigating ARPU decline. The company's key strengths are management's proven execution skills, nationwide GSM network and a strong brand, the report says. "The outcome of key pending regulatory issues remain uncertain with the expected long drawn-out legal battle. However, if Trai recommendations on spectrum are implemented, Bharti's FY09-10 EPS would

Broking house Company Action Date Price (Rs) ICICI Sec +   Sun Pharma. Buy Dec 20, 07 1,553.00 Reliance Money +   KLG Systel Limit Buy Dec 20, 07 986.00 Sharekhan Research +   Aurobindo Pharma Buy Dec 20, 07 914.00 Emkay +   HEG Ltd. Buy Dec 20, 07 681.00 Kotak Sec +   LIC Housing Fi Buy Dec 20, 07 450.00 MF Global PCG +   VIP Indus. Buy Dec 20, 07 235.00 Sharekhan +   Mold-Tek Technologi. Buy Dec 20, 07 215.00 Karvy Stock +   Shasun Chemicals Buy Dec 20, 07 115.00 IL&FS Investsmart +   Spicejet Ltd. Buy Dec 20, 07 88.00 Sharekhan +   Shiv-Vani Oil & Gas Buy Dec 19, 07 615.00 HDFC Securities +   Elecon Engg. Buy Dec 19, 07 400.00 KJMC Institutional +   Binani Cement Ltd. Buy Dec 19, 07 147.00 Angel Broking +   Nestle India Buy Dec 18, 07 1,699.00 Sharekhan +   Orbit Corporation Buy Dec 18, 07 1,060.00 ICICI Sec +   Mahi. &

MUMBAI: Be it Anil Ambani Group's Reliance Power or retail baron Kishore Biyani's Future Capital, their plans to hit the capital market with IPOs will have to wait till 2008 along with about four dozen other companies. Although the year that is drawing to a close has been good for IPOs with over 100 deals, including some mega public issues like that of DLF, as many as 50 companies that initiated their public issue process this year are still awaiting the necessary regulatory approvals. This includes the planned IPO of state-run National Hydroelectric Power Corp (NHPC), which filed its draft red herring prospectus over eight months ago in April and is among the longest pending public issues for the year. Among other high-profile IPOs in the queue are that of Reliance Power, which filed its DRHP on October 3 with market regulator SEBI. The regulator is currently awaiting "clarifications" from the IPO's lead managers for issuing its observations, which

    26717 GOPALA POLY 10.00 12 Month 75.00     532730 SGL 41.75 6 Month 166.00 average   531719 Bhagiradh Chemcials 105.75 1 Month 177.00 average   513530 Stelco 60.00 12 Month 333.00     507180 Kesar Enterprises 113.50 12 Month 450.00 average   511607 Sholka Info 30.40 1 Month 250.00

Kirloskar Ferrous Industries soared 7.56% to Rs 72.55 at 13:28 IST on market buzz the company has been allotted iron ore mines in Karnataka. The BSE Sensex was up 76.29 points, or 0.41%, to 19166.47. On BSE, 40.85 lakh shares of the scrip were traded. The stock had an average daily volume of 8.81 lakh shares on BSE in past one quarter. The scrip had touched a high of Rs 76.95 and a low of Rs 68.55 so far during the day. The stock had hit a 52-week high of Rs 73.80 on 14 December 2007 and a 52-week low of Rs 29 on 7 March 2007. The scrip had outperformed the market in the one month to 19 December 2007, adding 15.79% as against the Sensex's 0.98% decline. It had also outperformed the market in the past three months, soaring 54.35% against the Sensex's 16.79% rise. The small-cap metal firm has an equity capital of Rs 68.50 crore. Face value per share is Rs 5. At the current price of Rs 72.55, the scrip trades at a PE multiple of 27.90, based on Q2 September 200

Andrew Yule & Company was locked at upper limit of 5% at Rs 64.70 at 11:39 IST on BSE on reports the company is planning to rejig its various businesses. The BSE Sensex was up 122.15 points, or 0.64%, to 19214.93. On BSE, 2.56 lakh shares of the scrip were traded. The stock had an average daily volume of 55,377 shares on BSE in past one quarter. The scrip had touched a low of Rs 63.70 so far during the day. The stock had hit a 52-week high of Rs 82.70 on 12 December 2007 and a 52-week low of Rs 20.15 on 14 March 2007. The scrip had underperformed the market in the one month to 19 December 2007, sliding 10.65% as against the Sensex's 0.98% decline. It had, however, outperformed the market in the past three months, soaring 45.74% against the Sensex's 16.79% rise. The state-run diversified firm has an equity capital of Rs 58.27 crore. Face value per share is Rs 10. | As per reports, Andrew Yule & Company (AYCL) has decided to spin off its electrical and

IFCI slumped 22.79% to Rs 77.25 at 10:12 IST after the company, on Wednesday, 19 December 2007, called off the exercise to rope in a strategic partner through the private placement of 26% equity stake.. The BSE Sensex was up 69.79 points, or 0.37%, to 19161.23. On BSE, 1.44 crore shares of the scrip were traded. The stock had an average daily volume of 1.54 crore shares on BSE in past one quarter. The scrip had touched a high of Rs 86 and a low of Rs 73.25 so far during the day. The stock had hit a 52-week high of Rs 121.20 on 17 December 2007 and a 52-week low of Rs 10.75 on 20 December 2007. The scrip had outperformed the market in the one month to 18 December 2007, adding 1.52% as against the Sensex's 0.98% decline. It had also outperformed the market in the past three months, soaring 25.06% against the Sensex's 16.79% rise. The state-run non-banking finance company has an equity capital of Rs 639.99 crore. Face value per share is Rs 10. At the current pri

Suven Life Sciences was locked at upper limit of 20% at Rs 46.55 on BSE on reports that firm was in talks with two private equity firms to dilute up to 10% stake. On BSE, 66.18 lakh shares of the scrip were traded. The stock had an average daily volume of 1.76 lakh shares on BSE in past one quarter. The scrip had touched a low of Rs 38.85 so far during the day. The stock had hit a 52-week high of Rs 46.90 on 20 August 2007 and a 52-week low of Rs 27.08 on 20 December 2006. The scrip had outperformed the market in the one month to 17 December 2007, adding 19.38% as against the Sensex's 2.22% decline. It had also underperformed the market in the past three months, gaining 5.58% against the Sensex's 22.93% rise. The small-cap firm has an equity capital of Rs 11.56 crore. Face value per share is Rs 1. At the current price of Rs 46.55, the scrip trades at a PE multiple of 116.37, based on Q2 September 2007 annualised EPS of Rs 0.40. Suven Life Sciences reportedly plans to raise up

Company Name CMP* Price Target Upside (%) Aban Offshore 5017 5420 8.03 Axis (UTI) Bank 994 1054 6.03 Balaji Telefilms 348 427 22.70 BHEL 2561 3289 28.42 Grasim 3733 3950 5.81 Indo Tech Transformer 678 725 6.93 Maruti Suzuki 1042 1230 18.04 Mahindra & Mahindra 791 900 13.78 State Bank of India 2406 2680 11.38 Crompton 399 464 16.29